Harvard Bioscience (HBIO) Financials

Harvard Bioscience (NASDAQ:HBIO) is showing a mixed but improving operating profile in the latest quarter, while still carrying meaningful balance-sheet and leverage risks. In Q1 2026, revenue slipped year over year, but the company kept gross profit solid and continued to generate enough cash from non-cash add-backs to narrow the operating cash burn. The bigger issue remains below the operating line: interest and other non-operating costs are still overwhelming the business, leaving Harvard Bioscience with a quarterly net loss.

For retail investors, the key takeaway is that HBIO has made progress from the very weak results seen in early 2025, but the business is not yet consistently profitable and still depends on debt and working-capital management to stay afloat.

• Gross profit remained healthy in Q1 2026. Revenue of $20.8 million produced gross profit of $12.2 million, showing the company can still cover cost of goods sold reasonably well.
• Operating losses improved sharply from the prior year’s worst quarter. Operating income in Q1 2026 was a loss of $1.2 million, much better than the massive operating loss reported in Q1 2025 after impairment charges.
• Cash on the balance sheet increased. Cash and equivalents rose to $7.1 million at March 31, 2026, up from $5.5 million a year earlier.
• The company generated a meaningful recovery in quarterly operating cash flow versus earlier periods. Operating cash flow improved from a $0.1 million burn in Q4 2025 and a $0.8 million burn in Q2 2025 to a $0.7 million burn in Q1 2026, helped by non-cash add-backs.
• Inventory and receivables supported a larger current-asset base. Total current assets reached $47.5 million, giving the company some near-term asset backing.
• Revenue was broadly stable sequentially but down year over year. Q1 2026 revenue of $20.8 million was below Q4 2025’s $23.7 million and slightly below Q1 2025’s $21.8 million.
• Depreciation and amortization continue to do a lot of the heavy lifting in cash flow. Q1 2026 operating cash flow benefited from $1.8 million of combined depreciation and amortization, which masks the underlying earnings weakness.
• Debt restructuring likely helped liquidity in late 2025. Q4 2025 showed $40.0 million of new debt issuance alongside $37.5 million of debt repayment, indicating active balance-sheet management.
• HBIO remains unprofitable. Q1 2026 net loss was $3.4 million, or $0.77 per share.
• Interest and other non-operating costs are still a major drag. Q1 2026 had $2.1 million of total other expense, which pushed the company deeper into the red despite relatively controlled operating expenses.

Looking at the trend over the last four years, Harvard Bioscience has not yet established a stable earnings pattern. The company’s revenue has generally drifted lower from the 2023–2024 range into 2025–2026, while margins have been pressured by a combination of acquisition-related amortization, marketing expense, and financing costs. That was especially visible in Q1 2025, when a large impairment charge drove a steep loss and a sharp deterioration in equity.

The balance sheet remains the most important risk to monitor. At the end of Q1 2026, total liabilities were $67.9 million versus total equity of just $10.0 million. Long-term debt stood at $36.2 million, and current liabilities were $23.9 million. That leverage leaves little room for another revenue slump or margin setback.

Bottom line: HBIO has shown some stabilization in operations and cash generation, but it is still a highly leveraged turnaround story. Investors should watch for sustained revenue growth, lower interest burden, and continued improvement in operating cash flow before getting more constructive on the stock.